Spero Therapeutics, Inc. Increase (Decrease) in Other Noncurrent Liabilities
Spero Therapeutics, Inc. (SPRO) reported Increase (Decrease) in Other Noncurrent Liabilities of $91.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2026-03-26
- Spero Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2025-12-31 was $91.00K.
- Spero Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2025-09-30 was $0.00.
- Spero Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2025-06-30 was $0.00.
- Spero Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2025-03-31 was $0.00.
- Spero Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2025 was $91.00K.
- Spero Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2024 was -$87.00K.
- Spero Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2023 was -$9.00K.
- Spero Therapeutics, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2022 was -$42.00K.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 6 month | Increase (Decrease) in Other Noncurrent Liabilities 9 month | Increase (Decrease) in Other Noncurrent Liabilities 12 month |
|---|---|---|---|---|
| 2025-12-31 | $91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $91.00K derived: sum of 2 quarters · filed 2026-03-26 | $91.00K derived: sum of 3 quarters · filed 2026-03-26 | $91.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | -$13.00K derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | -$13.00K derived: sum of 3 quarters · filed 2026-03-26 | -$25.00K derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 | -$13.00K derived: sum of 2 quarters · filed 2026-03-26 | -$25.00K derived: sum of 3 quarters · filed 2026-03-26 | -$38.00K derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-12-31 | -$13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$25.00K derived: sum of 2 quarters · filed 2026-03-26 | -$38.00K derived: sum of 3 quarters · filed 2026-03-26 | -$87.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | -$12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$25.00K derived: sum of 2 quarters · filed 2025-11-13 | -$74.00K 10-Q · filed 2025-11-13 | -$48.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$62.00K 10-Q · filed 2025-08-12 | -$36.00K derived: sum of 3 quarters · filed 2025-08-12 | -$47.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$49.00K 10-Q · filed 2025-05-13 | -$23.00K derived: sum of 2 quarters · filed 2025-05-13 | -$34.00K derived: sum of 3 quarters · filed 2025-05-13 | -$47.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $15.00K derived: sum of 2 quarters · filed 2025-03-27 | $2.00K derived: sum of 3 quarters · filed 2025-03-27 | -$9.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | -$11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$24.00K derived: sum of 2 quarters · filed 2024-11-14 | -$35.00K 10-Q · filed 2024-11-14 | -$46.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | -$24.00K 10-Q · filed 2024-08-05 | -$35.00K derived: sum of 3 quarters · filed 2024-08-05 | -$45.00K derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | -$11.00K 10-Q · filed 2024-05-15 | -$22.00K derived: sum of 2 quarters · filed 2024-05-15 | -$32.00K derived: sum of 3 quarters · filed 2024-05-15 | -$43.00K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$21.00K derived: sum of 2 quarters · filed 2024-03-13 | -$32.00K derived: sum of 3 quarters · filed 2024-03-13 | -$42.00K 10-K · filed 2024-03-13 |
| 2022-09-30 | -$10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$21.00K derived: sum of 2 quarters · filed 2023-11-13 | -$31.00K 10-Q · filed 2023-11-13 | -$41.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$21.00K 10-Q · filed 2023-08-10 | -$31.00K derived: sum of 3 quarters · filed 2023-08-10 | -$41.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$10.00K 10-Q · filed 2023-05-11 | -$20.00K derived: sum of 2 quarters · filed 2023-05-11 | -$30.00K derived: sum of 3 quarters · filed 2023-05-11 | -$40.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$20.00K derived: sum of 2 quarters · filed 2023-03-30 | -$30.00K derived: sum of 3 quarters · filed 2023-03-30 | -$39.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | -$10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$20.00K derived: sum of 2 quarters · filed 2022-11-14 | -$29.00K 10-Q · filed 2022-11-14 | -$38.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$19.00K 10-Q · filed 2022-08-10 | -$28.00K derived: sum of 3 quarters · filed 2022-08-10 | -$38.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$9.00K 10-Q · filed 2022-05-16 | -$18.00K derived: sum of 2 quarters · filed 2022-05-16 | -$28.00K derived: sum of 3 quarters · filed 2022-05-16 | -$37.00K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$19.00K derived: sum of 2 quarters · filed 2022-03-31 | -$28.00K derived: sum of 3 quarters · filed 2022-03-31 | -$72.00K 10-K · filed 2022-03-31 |
| 2020-09-30 | -$10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$19.00K derived: sum of 2 quarters · filed 2021-11-10 | -$63.00K 10-Q · filed 2021-11-10 | -$71.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$53.00K 10-Q · filed 2021-08-05 | -$61.00K derived: sum of 3 quarters · filed 2021-08-05 | -$97.00K derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$44.00K 10-Q · filed 2021-05-06 | -$52.00K derived: sum of 2 quarters · filed 2021-05-06 | -$88.00K derived: sum of 3 quarters · filed 2021-05-06 | -$107.00K derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | -$8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$44.00K derived: sum of 2 quarters · filed 2021-03-11 | -$63.00K derived: sum of 3 quarters · filed 2021-03-11 | -$52.00K 10-K · filed 2021-03-11 |
| 2019-09-30 | -$36.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$55.00K derived: sum of 2 quarters · filed 2020-11-05 | -$44.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | -$19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$8.00K 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $11.00K 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |